LeMaitre Vascular (LMAT) Projected to Release Earnings on Tuesday

LeMaitre Vascular (NASDAQ:LMAT) is expected to be issuing its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to announce earnings of $0.8070 per share and revenue of $71.4730 million for the quarter. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 5:00 PM ET.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The firm had revenue of $66.55 million during the quarter, compared to analyst estimates of $66.67 million. During the same period in the previous year, the business posted $0.48 EPS. The business’s quarterly revenue was up 11.1% on a year-over-year basis. On average, analysts expect LeMaitre Vascular to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $101.32 on Monday. LeMaitre Vascular has a 52-week low of $79.00 and a 52-week high of $118.01. The stock has a market capitalization of $2.32 billion, a price-to-earnings ratio of 37.39, a price-to-earnings-growth ratio of 2.81 and a beta of 0.53. The company has a fifty day moving average of $97.15 and a 200-day moving average of $99.76. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 27,881 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the completion of the transaction, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at $155,428,765.11. This trade represents a 1.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bridget A. Ross sold 5,044 shares of LeMaitre Vascular stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total value of $560,388.40. Following the transaction, the director owned 3,942 shares of the company’s stock, valued at $437,956.20. The trade was a 56.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 54,453 shares of company stock worth $5,906,174 in the last 90 days. Insiders own 7.40% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds have recently bought and sold shares of LMAT. Geneos Wealth Management Inc. grew its position in LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC bought a new position in shares of LeMaitre Vascular in the second quarter worth approximately $47,000. Quarry LP lifted its stake in shares of LeMaitre Vascular by 267.2% in the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock worth $64,000 after buying an additional 529 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of LeMaitre Vascular during the fourth quarter valued at approximately $68,000. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of LeMaitre Vascular during the fourth quarter valued at approximately $80,000. Institutional investors own 84.64% of the company’s stock.

Analyst Upgrades and Downgrades

LMAT has been the subject of several recent research reports. Citizens Jmp boosted their price target on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Barrington Research reaffirmed an “outperform” rating and set a $120.00 price objective on shares of LeMaitre Vascular in a research note on Wednesday, June 3rd. Weiss Ratings cut LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, June 30th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $112.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.